Intra-Cellular Therapies

Intra-Cellular Therapies revenue

Intra-Cellular Therapies revenue was $22.81 m in FY, 2020

	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2019	FY, 2020
Revenue	$2.74 m	$577.3 k	$91.36 k	$330.7 k	$245.84 k	$60.61 k	$22.81 m
Growth		(78.91%)	(84.17%)	261.96%

	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2020	Q2, 2020
Revenue	$667.96 k	$167.79 k	$219.24 k	$124.41 k	$3.32 k	$57.39 k	$228.45 k	$4.36 k	$95.29 k	$114.74 k	$30.75 k	$1.08 m	$1.91 m

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

	FY, 2015	FY, 2014
License and collaboration revenue	$30.66 k	$547.55 k
Grant Revenue	$60.71 k	$29.76 k

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.